- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04818359
Movement and Health Beyond Care (MoviS) (MoviS)
Movement and Health Beyond Care, MoviS: Nutrition and Exercise Educational Programs for Breast Cancer Survivors
MoviS is a randomized controlled trial on the effect of aerobic exercise training on quality of life (QoL) among breast cancer (BC) survivors.
Patients randomized to the intervention arm will receive lifestyle recommendations (nutrition and exercise) and will undergo the MoviS Training program, whereas control arm patients will receive lifestyle recommendations. The MoviS Training program consists of 3 months, 3 times per week, aerobic exercise, which will be supervised both directly (2 days each week) and remotely (1 day each week). Exercise intensity (40% to 70% of heart rate reserve) and duration (20 to 60 mins) will be gradually increased throughout the training period. Both arms will receive counseling on psychological well-being.
The primary outcome is the improvement of QoL. The secondary outcome is the improvement of the health-related parameters.
Study variables will be sampled and compared between and within groups at the baseline, after the 3 month intervention period, ad interim in the short term (6 months) and long term (12 and 24 months).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND BC is the most common invasive cancer in women and evidence has shown that exercise can significantly improve the outcomes of BC survivors. MoviS (Movement and Health Beyond Care) is a randomized controlled trial that aims to evaluate the potential health benefits of exercise and proper nutritional habits.
Aim The present research study aims to assess the efficacy of aerobic exercise training on the QoL of high-risk BC survivors and the improvement of health-related factors.
Methods BC patients (sample size n=172), age 30-70 years, non-metastatic, stage 0-III, non-physically active, 6-12 months post-surgery, and post chemo- or radio-therapy, with a high risk of recurrence defined by one or more of the following criteria: BMI ≥ 25, diagnosis of metabolic syndrome, increased level of blood testosterone and insulin will be randomly allocated to the interventional arm (lifestyle recommendations and MoviS Training) or control arm (lifestyle recommendations). The MoviS Training consists of 3 months of aerobic exercise training (2 d/week of directly supervised and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min). Both arms will receive counseling on healthy lifestyle habits (nutrition and exercise) based on the World Cancer Research Fund (WCRF) 2018 guidelines through the DIANA-Web platform. All patients will also undergo psychological well-being counseling, which comprises evaluation for anxiety and depression.
The primary outcome is the improvement of the QoL assessed by the European Organization for Research and Treatment of Cancer QoL (EORTC QLQ-C30) questionnaire.
The secondary outcome is the improvement of health-related parameters such as: fatigue; anthropometric measurements and body composition; cardiac function indexes and heart rate variability; functional parameters (cardiorespiratory fitness, muscle flexibility and strength, coordination and posture variability, upper limb muscle viscoelastic characteristics); psychological well-being; metabolic, hormonal and inflammatory risk factors; gut microbiota; osteoporosis level; recurrences. Diet habits, physical activity level, pharmacological treatments and comorbidity will be recorded as confounding factors and covariates.
The hypothesis is that supervised exercise may improve QoL and health-related factors of BC survivors with a high risk of recurrence.
Data will be collected at baseline and after the 3 month intervention period, ad interim in the short term (6 months) and long term (12 and 24 months).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Elena Barbieri, PhD
- Phone Number: + 39 0722 303417
- Email: elena.barbieri@uniurb.it
Study Locations
-
-
PU
-
Urbino, PU, Italy, 61029
- Presidio Ospedaliero Unico "Santa Maria della Misericordia", Urbino
-
Urbino, PU, Italy, 61029
- University of Urbino Carlo Bo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Diagnosis of BC (stage 0-II-III, without metastases or recurrences diagnosis at recruitment).
- After surgery and chemotherapy and/or radiotherapy treatments.
- Maximum 12 months from surgical treatment.
- Minimum 6 months from the end of chemotherapy.
- Risk of recurrence will be identified with meeting at least 1 of the following criteria: BMI at diagnosis ≥ 25 kg/m2, testosterone ≥ 0.4 ng/mL (for women); serum insulin ≥ 25 µU/mL (170 pmol/L); metabolic syndrome (at least 3 of the following 5 factors): a. glycemia ≥ 100 mg/dL (6.05 mmol/L); b. triglycerides ≥150 mg/dL (1.69 mmol L); c. HDL-C <50 mg/dL (1.29 mmol/L) (woman), <40 mg/dL (1.04 mmol/L) (man); d. waist circumference ≥ 80 cm (woman), ≥ 90 cm (man); e. blood pressure ≥ 130/85 mmHg.
- Non-physically active: subjects who were not regularly active (assessed by IPAQ) for at least 6 months.
Exclusion criteria:
- Not suitable for non-competitive physical activity after the cardiological medical examination.
- Disabling pneumological, cardiological, neurological, orthopedic comorbidities and mental illness that prevent the exercise performance.
- Treatment with drugs that alter the heart rate response to exercise.
- Treatment with antidepressant drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional Arm
Supervised exercise program: MoviS Training.
Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
|
Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).
|
No Intervention: Control Arm
Lifestyle (nutrition and exercise) counseling based on WCRF 2018 recommendations; psychological well-being counseling which comprises evaluation for anxiety and depression.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life assessed by questionnaire
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
Scores ranging from 0 to 100; higher scores indicate better quality of life.
|
Baseline - after 3, 6, 12, 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fatigue
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in fatigue perception assessed by brief fatigue inventory (BFI) questionnaire.
The score of the questionnaire ranges from 0 to 90.
A higher score means more severe fatigue.
|
Baseline - after 3, 6, 12, 24 months
|
Anthropometry
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change body mass index (BMI) expressed as body mass (kg) / height2 (m2).
|
Baseline - after 3, 6, 12, 24 months
|
Body composition
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change fat mass (%) assessed by bioelectrical impedance analysis.
|
Baseline - after 3, 6, 12, 24 months
|
Cardiac function indexes
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in the global longitudinal strain (%) assessed by echocardiography.
|
Baseline - after 3, 6, 12, 24 months
|
Heart rate variability
Time Frame: Baseline - after 3 months
|
Change in heart rate variability assessed by 24-Holter monitoring.
|
Baseline - after 3 months
|
Cardiorespiratory fitness
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in cardiorespiratory fitness assessed by estimated maximal oxygen uptake (mL/min/kg).
|
Baseline - after 3, 6, 12, 24 months
|
Flexibility
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in muscle flexibility assessed by sit & reach test (m).
|
Baseline - after 3, 6, 12, 24 months
|
Muscular fitness
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change strength assessed by isometric hand grip strength test (kg).
|
Baseline - after 3, 6, 12, 24 months
|
Proprioceptive recalibration
Time Frame: Baseline - after 6 months
|
Change assessed by stabilometry (Mean Velocity) (mm2/sec2).
|
Baseline - after 6 months
|
Posture balance
Time Frame: Baseline - after 6 months
|
Change assessed by stabilometry (Romberg Quotient test-European variant) (% over or under 100).
|
Baseline - after 6 months
|
Upper limb muscles viscoelastic characteristics
Time Frame: Baseline - after 3 months
|
Change in the muscle properties of the pectoralis major, upper trapezius, and sternoclavicular mastoid muscle assessed by a hand-held myotonometer.
|
Baseline - after 3 months
|
Psychological well-being
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in mood profile assessed by Profile of Mood States (POMS) questionnaire.
The POMS questionnaire gives a 5-point Likert scale; a higher score indicates increased negative mood.
|
Baseline - after 3, 6, 12, 24 months
|
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Index
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in HOMA-IR Index calculated as HOMA-IR = (FPI × FPG)/22.5, where FPI is fasting plasma insulin concentration (mU/l) and FPG is fasting plasma glucose (mmol/L), or as HOMA-IR = (FPI × FPG)/405 if fasting plasma glucose is expressed in mg/dL.
|
Baseline - after 3, 6, 12, 24 months
|
Insulin-like growth factor (IGF-1)
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in IGF-1 assessed by blood samples (µg/L).
|
Baseline - after 3, 6, 12, 24 months
|
C-reactive protein
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in high sensitivity C-reactive protein assessed by blood samples (mg/L).
|
Baseline - after 3, 6, 12, 24 months
|
Gut microbiota
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in microbial diversity (species diversity %) assessed by next-generation sequencing (NGS) of the V3-V4 region of the 16S rDNA gene.
|
Baseline - after 3, 6, 12, 24 months
|
Osteoporosis level
Time Frame: Baseline - after 12 and 24 months
|
Change in computerized bone mineralometry assessed by T-Score (Normal: +2.5> T-score> -1.0; Osteopenia: -1.0> T-score> -2.5; Osteoporosis: T-score <-2.5;
Severe osteoporosis: T-score <-2.5 with one or more fragility fractures).
|
Baseline - after 12 and 24 months
|
Recurrences
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Recurrences free interval defined as time from registration to time of documented recurrent disease.
|
Baseline - after 3, 6, 12, 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diet habits
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in dietary intake assessed by questionnaire (14-item Mediterranean diet adherence screener, MEDIET) through DIANAWeb platform.
Higher levels (8-9, or >10 points in the 14-item score) indicates adherence to the Mediterranean diet.
|
Baseline - after 3, 6, 12, 24 months
|
Physical activity level
Time Frame: Baseline - after 3, 6, 12, 24 months
|
Change in physical activity level assessed by the sensewear armband activity monitor and by the international physical activity questionnaire (IPAQ).
The output of both assessments expressed in metabolic equivalents (METs)-min/week.
|
Baseline - after 3, 6, 12, 24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UniUrb_21/10.07.2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Survivors
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBreast Cancer SurvivorsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer SurvivorsUnited States
-
University of FloridaNot yet recruiting
-
Istanbul Medeniyet UniversityNot yet recruitingBreast Cancer SurvivorsTurkey
-
Memorial Sloan Kettering Cancer CenterBaruch College City University of New YorkActive, not recruitingBreast Cancer SurvivorsUnited States
-
Istanbul Medeniyet UniversityNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterCity of Hope Medical Center; The New School for Social ResearchActive, not recruitingBreast Cancer SurvivorsUnited States
-
National Taipei University of Nursing and Health...CompletedBreast Cancer SurvivorsTaiwan
-
University of Texas at AustinCompleted
Clinical Trials on MoviS Training
-
University of Trás-os-Montes and Alto DouroCompletedLipid Metabolism Disorders | Sarcopenia | Osteoporosis | Overweight and Obesity | Personal Satisfaction | Hypertension With Complications and Secondary HypertensionPortugal
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedHypertension | Diabetes | Peripheral Arterial DiseaseBrazil
-
New Jersey Institute of TechnologyRutgers, The State University of New JerseyCompletedHemiplegia | Hemiparesis | Cerebrovascular AccidentUnited States
-
Riphah International UniversityRecruiting
-
University of PittsburghEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Lebanese UniversityCompletedHeart Failure | Quality of Life | Cardiac Rehabilitation | Aerobic Exercise | Exercise Intolerance | Respiratory Muscle Training | Strength Training
-
Poznan University of Physical EducationPoznan University of Medical Sciences; National Science Centre, PolandActive, not recruitingHealthy Athletes Aged 18-35 YearsPoland
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedHyperglycemia | Diabetes Mellitus, Type 2Norway